María Koehler

11.3k total citations · 4 hit papers
112 papers, 7.0k citations indexed

About

María Koehler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, María Koehler has authored 112 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in María Koehler's work include HER2/EGFR in Cancer Research (37 papers), Advanced Breast Cancer Therapies (34 papers) and Cancer Treatment and Pharmacology (24 papers). María Koehler is often cited by papers focused on HER2/EGFR in Cancer Research (37 papers), Advanced Breast Cancer Therapies (34 papers) and Cancer Treatment and Pharmacology (24 papers). María Koehler collaborates with scholars based in United States, United Kingdom and Canada. María Koehler's co-authors include Cynthia Huang Bartlett, Nicholas C. Turner, Massimo Cristofanilli, Sherene Loi, Nadia Harbeck, Jungsil Ro, Ke Zhang, Sunil Verma, Hiroji Iwata and Fabrice André and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

María Koehler

109 papers receiving 6.8k citations

Hit Papers

Fulvestrant plus palbociclib versus fulvestrant plus p... 2010 2026 2015 2020 2016 2015 2010 2016 400 800 1.2k

Peers

María Koehler
Comparison fields: 5 of 120
  • Oncology 5.0k
  • Pulmonary and Respiratory Medicine 3.4k
  • Cancer Research 1.9k
  • Molecular Biology 1.5k
  • Genetics 1000
Arlene Chan Australia
Beth Overmoyer United States
Erika Hamilton United States
Eva Ciruelos Spain
Mark Benyunes United States
Petri Bono Finland
Dimosthenis Skarlos Greece
Roberto Hegg Brazil
Gwen Fyfe United States
Alex Bajamonde United States
Arlene Chan Australia View profile →
Citations per field, relative to María Koehler
María Koehler · 1×
Citations per year, relative to María Koehler
María Koehler · 1×

Countries citing papers authored by María Koehler

Since Specialization
Citations

This map shows the geographic impact of María Koehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Koehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Koehler more than expected).

Fields of papers citing papers by María Koehler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Koehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Koehler. The network helps show where María Koehler may publish in the future.

Co-authorship network of co-authors of María Koehler

This figure shows the co-authorship network connecting the top 25 collaborators of María Koehler. A scholar is included among the top collaborators of María Koehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Koehler. María Koehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma npj Precision Oncology Natalie Y.L. Ngoi, Ian M. Silverman et al. 1
2 IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors. Journal of Clinical Oncology Alex A. Adjei, Kwok‐Kin Wong et al. 3
3 Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) JNCI Journal of the National Cancer Institute Elisa Fontana, Ezra Y. Rosen et al. 7
4 Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib Clinical Cancer Research Ezra Y. Rosen, Timothy A. Yap et al. 4
5 PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer Annals of Oncology Erica L. Mayer, Angela DeMichele et al. 7
6 Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial breakdown → The Lancet Oncology Massimo Cristofanilli, Nicholas C. Turner et al. 1247
7 Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006) Journal of Clinical Oncology Miguel Martín, Moshe Inbar et al. 1
8 Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting Chinese Journal of Cancer Roger Luo, Jian Ding et al. 2
9 Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer breakdown → Journal of Clinical Oncology Kimberly Blackwell, Harold J. Burstein et al. 701
10 Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor Clinical Cancer Research Maurizio Scaltriti, Sarat Chandarlapaty et al. 114
11 Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer Journal of Clinical Oncology Richard S. Finn, Michael F. Press et al. 144
12 Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer Journal of Clinical Oncology Angelo Di Leo, Henry Gómez et al. 345
13 HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer Clinical Cancer Research Michael F. Press, Richard S. Finn et al. 134
14 Rhabdomyolysis in allogeneic peripheral blood stem cell donors Vox Sanguinis Julie Schanz, Claudia Wolf et al. 4
15 Diminished Antibody Response to Hepatitis B Immunization in Children With Sickle Cell Disease Journal of Pediatric Hematology/Oncology Jeffrey D. Hord, María Koehler et al. 13
16 The Use of Counterflow Centrifugal Elutriation for the Depletion of T Cells from Unrelated Donor Bone Marrow Journal of Hematotherapy Steven Neudorf, Witold B. Rybka et al. 4
17 Complications of Bacteremia Due to Stomatococcus mucilaginosus in Neutropenic Children Clinical Infectious Diseases Scott Henwick, María Koehler et al. 26
18 Childhood Acute Lymphoblastic Leukemia Immunophenotypes and their Prognostic Significance: Experience of the IGCI-Study in 389 Children Leukemia & lymphoma Jerzy Hołowiecki, María Koehler et al. 2
19 The effects of long term methotrexate therapy on the gonadal function and morphology. PubMed María Koehler et al. 1
20 Effects of Methotrexate on Rabbit Testes Part 2: Hormonal Changes Pediatric Hematology and Oncology María Koehler, U. Heinrich et al. 11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026